GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Activist investor 7Square urges Nuernberger to explore takeover offers - Global Banking & Finance Review
The featured image illustrates the financial landscape as activist investor 7Square pressures Nuernberger to evaluate rival takeover offers, emphasizing the ongoing competition in the insurance sector.
Finance

Australia's Mayne Pharma jumps to 1-year high on $408 million Gedeon Richter takeover

Published by Global Banking & Finance Review

Posted on November 17, 2026

2 min read

· Last updated: November 17, 2026

Add as preferred source on Google

Mayne Pharma Shares Soar on $408 Million Gedeon Richter Takeover Bid

Gedeon Richter's Acquisition of Mayne Pharma: Key Details and Market Impact

Overview of the Takeover Bid

Nov 17 (Reuters) - Mayne Pharma said on Tuesday that Hungarian drugmaker Gedeon Richter had agreed to buy the Australian firm for an equity value of about A$604 million ($407.76 million), sending its shares soaring 86% to a one-year high.

The deal put the stock on track for its best session on record, if the current gains hold, with shares last trading at A$5.97.

Gedeon Richter has offered A$6.40 per Mayne share, a 99.4% premium to the stock's last close on Monday.

Board Response and Shareholder Interests

"The board has carefully considered the proposal from Richter and has unanimously concluded that it is in the best interests of Mayne Pharma shareholders, in the absence of a Superior Proposal and subject to the independent expert's conclusion," said Mayne Pharma Chair Bruce Robinson.

The scheme is subject to certain regulatory approvals, among other conditions, including completion of the sale of its International business segment to Evaris Pharma.

Strategic Rationale and Future Prospects

"Mayne's existing portfolio – including our estetrol-based innovative combination contraceptive pill – and its commercial footprint provide a strong base to build on and will allow us to bring new treatments to millions of women in the United States across several therapeutic segments, where there is significant unmet medical need," Richter Deputy CEO László Kovács said.

Background: Previous Acquisition Attempts

The deal follows a nearly two-year saga between US-based Cosette Pharmaceuticals and Mayne, during which the former sought to walk away from its A$672 million offer, citing a "material adverse change" in the Australian drugmaker's business and finances.

Australia had blocked the deal last year on national interest grounds after Cosette threatened to shut Mayne's Adelaide manufacturing plant, which employs about 200 people and is one of the company's two main factories.

Mayne Pharma's Business Focus

Mayne makes branded and generic drugs focused on women's health, dermatology and infectious diseases.

Cosette's offer valued Mayne shares at A$7.40 apiece. As of Monday's close, the stock had lost more than half its value since the offer was first announced.

Additional Information

($1 = 1.4813 Australian dollars)

(Reporting by Sneha Kumar in Bengaluru; Editing by Sahal Muhammed and Sherry Jacob-Phillips)

Key Takeaways

  • Gedeon Richter’s all‑cash bid of A$6.40/share values Mayne at A$604 million and represents a 99.4% premium to the 16 Nov close, and 124% above 30‑day VWAP (smallcaps.com.au).
  • The Mayne board unanimously supports the scheme, contingent on no superior proposal and an independent expert’s endorsement; key conditions include prior sale of its International segment to Evaris Pharma and receipt of regulatory approvals (smallcaps.com.au).
  • Mayne’s transformation strategy includes divesting its International/Manufacturing arm for A$55.5 million to focus on high‑margin U.S. Women’s Health, Dermatology and DistributeRx businesses (company-announcements.afr.com).

References

Frequently Asked Questions

Who is acquiring Mayne Pharma?
Hungarian drugmaker Gedeon Richter has agreed to acquire Australia’s Mayne Pharma for A$604 million (about $408 million).
What is the premium offered by Gedeon Richter on Mayne Pharma shares?
Gedeon Richter offered A$6.40 per Mayne share, a 99.4% premium to the previous close.
What conditions must be met for the Mayne Pharma takeover?
The scheme is subject to regulatory approvals and completion of the sale of Mayne’s International business segment to Evaris Pharma.
What impact did the takeover news have on Mayne Pharma’s share price?
Mayne Pharma shares soared 86% to A$5.97, reaching a one-year high following the announcement.
Why was a previous takeover bid for Mayne Pharma blocked?
Australia blocked Cosette Pharmaceuticals’ prior bid due to national interest concerns after Cosette threatened to shut Mayne's Adelaide plant.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category